<span item_type="fundamental" item_id="a4f6803802aaf6951c5ea6a319e1ccdb" counter_id="ST/US/TSVT" env="prod"></span><span item_type="announcement" item_id="513568788921975041" env="prod"></span><p>Revenue: As of FY2025 Q1, the actual value is USD 22.94 M, beating the estimate of USD 13.96 M.</p><p>EPS: As of FY2025 Q1, the actual value is USD 0.01, beating the estimate of USD -0.17.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Total Revenue</strong>: $22.9 million for the three months ended March 31, 2025, compared to $12.4 million for the same period in 2024, an increase of $10.5 million primarily due to increased collaborative arrangement revenue from BMS driven by increased Abecma sales and decreased cost of goods sold.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000037/tsvt-20250331.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Income (Loss)</strong>: Net income of $0.5 million for the three months ended March 31, 2025, compared to a net loss of $52.7 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000037/tsvt-20250331.htm"></span></li><li><strong>Research and Development Expenses</strong>: $5.4 million for the three months ended March 31, 2025, compared to $43.9 million for the same period in 2024, a decrease of $38.5 million primarily due to decreased employee compensation and facilities costs following the Regeneron Transaction.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000037/tsvt-20250331.htm"></span></li><li><strong>Selling, General and Administrative Expenses</strong>: $14.8 million for the three months ended March 31, 2025, compared to $12.7 million for the same period in 2024, an increase of $2.2 million primarily due to increased facilities costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000037/tsvt-20250331.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: - $10.973 million for the three months ended March 31, 2025, compared to - $41.877 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000037/tsvt-20250331.htm"></span></li><li><strong>Net Cash Provided by Investing Activities</strong>: $39.627 million for the three months ended March 31, 2025, compared to $21.833 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000037/tsvt-20250331.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Abecma U.S. Collaboration Profit (Loss) Share</strong>: The company recognized $19.144 million in collaborative arrangement revenue from the Abecma U.S. collaboration with BMS for the three months ended March 31, 2025, compared to a share of collaboration loss of $1.230 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000037/tsvt-20250331.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to focus on the commercialization and development of Abecma, with expectations to incur significant expenses to expand site footprint, educate physicians, and support quality control of LVV.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000037/tsvt-20250331.htm"></span></li><li><strong>Non-Core Business</strong>: The company completed the sale of its oncology and autoimmune research and development programs to Regeneron and its gene therapy program to Novo Nordisk as part of its strategic realignment.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1860782/000186078225000037/tsvt-20250331.htm"></span></li></ul>

2seventy bio | 10-Q: FY2025 Q1 Revenue Beats Estimate at USD 22.94 M